Overview

Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide

Status:
COMPLETED
Trial end date:
2018-09-07
Target enrollment:
Participant gender:
Summary
The purpose of this study is: * To assess the effect of BIA 5 1058 400 mg on furosemide pharmacokinetics (PK). * To assess the effect of furosemide 40 mg on the PK of BIA 5 1058.
Phase:
PHASE1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Furosemide